Dyadic Q3 revenue $397K (-55% YoY); cash $8.2M; Phase 1 top-line results expected Dec 2023

DYADIC INTERNATIONAL INC

Revenue $397K vs $880K YoY; net loss $1.614M ($0.06) vs $1.809M ($0.06).
Cash $8.2M as of Sep 30, down from $12.7M at Dec 31, 2022.
Received $0.6M upfront in Oct for Dapibus animal-free dairy enzyme license.
DYAI-100 Phase 1 top-line results expected Dec 2023; no major safety concerns.
New collaboration with Mass General/DoD ($5.88M grant) and bYoRNA for mRNA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.